,Preformulation, Cardiovascular Safety Pharmacology, Drug-drug interactions, In vitro DART, Infusion Technologies in NHP, LC-MS/MS of proteins
A "unique" industry-driven platform that reduces the Attrition you might encounter when selecting the best item from among thousands.
In Seoul in April two meetings in the biotech, pharma and biomedical area. Accelera will participate with several initiatives.
Accelera will be present at The SOT 56th Annual Meeting and ToxExpo in Baltimora March 12-16, 2017 with our Safety Alliance Partner.
Proud to be among DNDi partners. DNDi and partners developed a breakthrough treatment for sleeping sickness
Accelera expands to Japanese market by leveraging strategic alliance with Safety Alliance,a selected number of high-quality, complementary CROs, one point of access for full preclinical development and regulatory package